Dostarlimab

• CAT Number: I042245
• CAS Number: 2022215-59-2
• Purity: ≥95%

Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively[1].
Dostarlimab (10-10000 ng/mL) binds to native PD-1 receptor expressed on human and cynomolgus monkey CD3+ T cells in a dose-dependent manner[1].
Dostarlimab (0-375 nM; 48 h) increases IL-2 production with an EC50 of approximately 1 nM in a human CD4+ T-cell MLR assay, increases IL-2 production with an EC50 of approximately 0.1 nM in staphylococcal enterotoxin B (SEB)-stimulated PBMCs, enhances interferon (IFN)-γ release with an EC50 of approximately 0.5 nM[1].
Dostarlimab (200 µg/mouse; i.p.; twice weekly for 35 days) shows antitumor activity in humanized mouse models[1].

Reference

[1]. Kumar S, et al. Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models. MAbs. 2021 Jan-Dec;13(1):1954136.
 [Content Brief]